Clinical effectiveness of the respimat ® inhaler device in managing chronic obstructive pulmonary disease: Evidence when compared with other handheld inhaler devices

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 129-139

  Ram, Felix S F ^a   Carvallho, Celso R ^b   White, John ^c  

^a MASSEY UNIVERSITY   (New Zealand)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c YORK HOSPITAL   (United Kingdom)

Author keywords

Aerosol cloud; COPD; Handheld inhaler devices; Respimat

Indexed keywords

BRONCHODILATING AGENT; FENOTEROL PLUS IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE; SALBUTAMOL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; METERED DOSE INHALER; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; XEROSTOMIA; AEROSOL; AGED; DRUG EFFECT; EQUIPMENT DESIGN; EVIDENCE BASED MEDICINE; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; AEROSOLS; AGED; BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; EVIDENCE-BASED MEDICINE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; METERED DOSE INHALERS; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 79959812842     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S8092     Document Type: Review

References (30)

1. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381-390.
2. Schurmann W, Schmidtmann S, Moroni P, et al. Respimat Soft Mist inhaler versus hydrofuoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4(1):53-61.
3. TM Inhaler. Int J Pharm. 2004;283(1-2):1-9.
4. Spallek M, Hochrainer D, Wachtel H. Optimizing nozzles for soft mist inhalers. Respiratory Drug Delivery. 2002;VIII(2):375-378.
5. TM inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273-282.
6. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12:S19-S24.
7. Newman S P, Brown J, Steed K P, et al. Lung deposition of fenoterol and funisolide delivered using a novel device for inhaled medicines: comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957-963.
8. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264-272.
9. Worth Longest P, Hindle M. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach. J Aerosol Med. 2009;22(2):99-112.
10. Steed K P, Towse LJ, Freund B, Newman S P. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser. Eur J Pharm Sci. 1997;5(2): 55-61.
11. TM inhaler compared with turbohaler or pMDI. J Allergy Clin Immun. 2006;117(2): S82-S82.
12. TM inhaler in patients with COPD. Resp Med. 2004;98(5):387-397.
13. ® (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration. 2000;67(3):306-314.
14. Pavia D, Moonen D. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler. J Aerosol Med. 1999;12: S33-S39.
15. Zuwallack R, De Salvo MC, Kaelin T, et al. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. Respir Med. 2010;104(8):1179-1188.
16. Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763-770.
17. ® (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Resp Med. 2000;94(5):490-495.
18. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010; 104(10):1460-1472.
19. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis. 2010;5:197-208.
20. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester: John Wiley & Sons Ltd; 2005.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
22. Review Manager (RevMan). Version 4.3 for Windows [program]. Copenhagen: The Cochrane Collaboration; 2006.
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4): 719-748.
24. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(4): 559-565.
25. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 microg via Respimat and 18 microg via HandiHaler; Efficacy and safety in Japanese COPD patients. Resp Med. 2010;104(2):228-236.
26. ® in COPD patients. Resp Med. 2009;103(1): 22-29.
27. Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1:CD002170.
28. Wright J, Brocklebank D, Ram F. Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Saf Health Care. 2002;11(4):376-382.
29. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-209.
30. Lareau S, Yawn B P. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:401-406.